Experimental treatment of NRAS-mutated neurocutaneous melanocytosis with MEK162, a MEK-inhibitor - Wikidata - awgldk - TriplyDB

Experimental treatment of NRAS-mutated neurocutaneous melanocytosis with MEK162, a MEK-inhibitor

Experimental treatment of NRAS-mutated neurocutaneous melanocytosis with MEK162, a MEK-inhibitor

http://www.wikidata.org/entity/Q21195751

about

Acute Inhibition of MEK Suppresses Congenital Melanocytic Nevus Syndrome in a Murine Model Driven by Activated NRAS and Wnt Signaling.MEK inhibition appears to improve symptom control in primary NRAS-driven CNS melanoma in children.The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent Oncogenic codon 13 NRAS mutation in a primary mesenchymal brain neoplasm and nevus of a child with neurocutaneous melanosis.Update on Molecular Pathology of Cutaneous Melanocytic Lesions: What is New in Diagnosis and Molecular Testing for Treatment?Druggable targets in pediatric neurocutaneous melanocytosis: Molecular and drug sensitivity studies in xenograft and ex vivo tumor cell culture to identify agents for therapy.Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2015 MauiDerm Meeting NRAS(Q61K) mutated primary leptomeningeal melanoma in a child: case presentation and discussion on clinical and diagnostic implications The Antipancreatic Cancer Activity of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2.Primary melanocytic tumors of the central nervous system: a review with focus on molecular aspects.Pigmented Lesions of the Nervous System and the Neural Crest: Lessons From Embryology.Combination treatment with perifosine and MEK-162 demonstrates synergism against lung cancer cells in vitro and in vivo.Tumor-specific hepatic stellate cells (tHSCs) induces DIgR2 expression in dendritic cells to inhibit T cells.Leptomeningeal melanomatosis associated with neurocutaneous melanosis: an autopsy case report.

P2860

Q30661575-8290EF6E-C5C0-4C86-8CF8-B5CDE5D1B19F Q33577613-7F5A192A-49DD-4D13-B36B-3B561268A27E Q33728258-DBD0EE45-5976-4082-8062-07243EF3E87B Q34402363-D4582BBD-39B0-4936-B8FC-1791E187B50B Q34928118-920C7769-9813-42BF-B46E-FEFF0B754B79 Q35419895-35400062-13F0-4BAC-86FD-D8B0F6ECCEF5 Q35822379-C6437DA1-E32D-4E20-90A6-ED8FD6571737 Q36083348-6B25F571-F853-4EBB-9625-905B3B0B5AA0 Q36123027-505AB3CB-3EF1-4E63-94EE-4812CB5E6806 Q38297995-9B0EE469-6F82-46D0-B337-20C9EA281EEA Q38583968-9240F1E3-E07E-4896-88CD-14F562D18501 Q38907955-4C4E706B-D975-4809-8EC1-5F54F4F084D5 Q41549602-38A0758B-10DD-4E82-8672-3535F9B5B49B Q48408000-547B375C-6C97-48A0-9B90-740A7AFB1BB7

P2860

Experimental treatment of NRAS-mutated neurocutaneous melanocytosis with MEK162, a MEK-inhibitor

http://www.wikidata.org/entity/Q21195751

description

2014 nî lūn-bûn

@nan

2014 թուականին հրատարակուած գիտական յօդուած

@hyw

2014 թվականին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

name

Experimental treatment of NRAS ...... s with MEK162, a MEK-inhibitor

@ast

Experimental treatment of NRAS ...... s with MEK162, a MEK-inhibitor

@en

Experimental treatment of NRAS ...... s with MEK162, a MEK-inhibitor

@en-gb

Experimental treatment of NRAS ...... s with MEK162, a MEK-inhibitor

@nl

type

label

Experimental treatment of NRAS ...... s with MEK162, a MEK-inhibitor

@ast

Experimental treatment of NRAS ...... s with MEK162, a MEK-inhibitor

@en

Experimental treatment of NRAS ...... s with MEK162, a MEK-inhibitor

@en-gb

Experimental treatment of NRAS ...... s with MEK162, a MEK-inhibitor

@nl

prefLabel

Experimental treatment of NRAS ...... s with MEK162, a MEK-inhibitor

@ast

Experimental treatment of NRAS ...... s with MEK162, a MEK-inhibitor

@en

Experimental treatment of NRAS ...... s with MEK162, a MEK-inhibitor

@en-gb

Experimental treatment of NRAS ...... s with MEK162, a MEK-inhibitor

@nl

P1433

Q21195751-B8AEE24C-5B63-4E5B-BE91-2633FD1B5B7E

P1476

Q21195751-7EB2512D-6283-4531-A5F1-84096F87C4A6

P2093

Q21195751-057BBDBF-CEA1-4C3C-8814-1BF3B0F03D19

Q21195751-0D398820-ACC8-480F-8DC1-B41B3D6F3BD7

Q21195751-1F36CE65-D33E-48D8-87FC-71C3505ED186

Q21195751-878E07CE-71A0-4210-8C23-DD9B6D082CE6

Q21195751-931EF016-BE74-4331-BC25-9B074A13E710

Q21195751-A2702FC8-6706-4390-9B25-30B6C4824D4A

Q21195751-DE61A998-D051-425F-BA9E-A62B54FEE3DF

Q21195751-E540F863-AB76-4662-AE7E-0228C18DEF78

Q21195751-E5CAE1E3-8CFA-4F35-A817-D20178FF5A1F

P2860

Q21195751-3656A30A-A18C-4625-8C32-E229AE1EBCAC

Q21195751-568103D4-2D7F-4E16-8171-9A1CEA741263

Q21195751-5F8507FC-D132-4E73-89B1-18EAF26CC798

Q21195751-634ADDBC-3532-4E66-B9B7-519B35E62D14

Q21195751-6A7AC972-AB8A-4174-91D6-C71EFC9A2382

Q21195751-800EC2AB-F711-4CE3-85AA-7F8206FE8849

Q21195751-CDF265C0-B690-467B-90A7-9F505C6AA32E

Q21195751-E3590BC4-29C3-44E2-9C07-286581323723

Q21195751-EC560495-FD5B-4886-B68E-EEEA2D925F52

Q21195751-F586FE09-5EC8-4240-9C7B-2EFADFA6B826

P2888

Q21195751-9F9C7000-66AC-4071-8B75-435DAC39F0FC

P304

Q21195751-B26EA77A-205B-4B33-997E-B926381C1120

P31

Q21195751-26947d0a-1450-4ad1-85f8-d3c6ddeaa6f8

Q21195751-9B609567-EF22-4A46-BC77-E8FFFE652D42

P3181

Q21195751-921E7BF4-060E-474F-BFC5-A6696D6CBDBC

P356

Q21195751-42CB620A-DADD-42BE-A3BE-DB7DFF43E31E

P407

Q21195751-16E9C011-76BF-495F-BFC2-562D893E8D76

P433

Q21195751-05AF51F4-B9F7-45AB-A29C-05D575C5793E

P478

Q21195751-8D74A971-E715-4F54-8DD4-96C0648C5D7E

P50

Q21195751-069FF890-58C8-4436-883F-016BC4299620

Q21195751-15A69BED-16DC-400F-B7FE-F2374EA6335D

Q21195751-59E40754-FA5B-4831-AE3F-48CB288CEB5C

P577

Q21195751-0AA37DD3-1859-4572-9FCC-ED10829DB50E

P5875

Q21195751-B2D7A4EE-5BA3-4617-A512-495F0FE4DCDE

P6179

Q21195751-BE600112-57C9-46E1-A5E4-4E6A94784A55

P698

Q21195751-F1416450-2303-4748-AD47-BC9B033E9780

P932

Q21195751-52A14348-E11F-4620-B3C6-93CE286D2ED3

P3181

P356

P1433

Acta neuropathologica communications

P1476

Experimental treatment of NRAS ...... s with MEK162, a MEK-inhibitor

@en

P2093

Benno Küsters

http://www.w3.org/2001/XMLSchema#string

Carla Ml van Herpen

http://www.w3.org/2001/XMLSchema#string

Hans Delye

http://www.w3.org/2001/XMLSchema#string

Heidi Vn Küsters-Vandevelde

http://www.w3.org/2001/XMLSchema#string

Jos Rijntjes

http://www.w3.org/2001/XMLSchema#string

Melika Djafarihamedani

http://www.w3.org/2001/XMLSchema#string

Michel A Willemsen

http://www.w3.org/2001/XMLSchema#string

Patricia Jta Groenen

http://www.w3.org/2001/XMLSchema#string

Willeke Am Blokx

http://www.w3.org/2001/XMLSchema#string

P2860

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.

Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system.

Multiple congenital melanocytic nevi and neurocutaneous melanosis are caused by postzygotic mutations in codon 61 of NRAS

Neurocutaneous melanosis in association with Dandy-Walker malformation: case report and literature review.

Neurocutaneous melanosis: definition and review of the literature.

Primary melanoma of the CNS in children is driven by congenital expression of oncogenic NRAS in melanocytes.

Neuropathology of neurocutaneous melanosis: histological foci of melanotic neurones and glia may be undetectable on MRI.

GNA11 and N-RAS mutations: alternatives for MAPK pathway activating GNAQ mutations in primary melanocytic tumours of the central nervous system.

Vemurafenib for leptomeningeal melanomatosis.

Long-term effects of BRAF inhibitors in melanoma treatment: friend or foe?

P2888

P304

41

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

32826

http://www.w3.org/2001/XMLSchema#string

P356

10.1186/2051-5960-2-41

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

Annelieke Ecab Willemsen

Pieter Wesseling

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261515188

http://www.w3.org/2001/XMLSchema#string

P6179

1014937598

http://www.w3.org/2001/XMLSchema#string

P698

24713450

http://www.w3.org/2001/XMLSchema#string

P932

4023633

http://www.w3.org/2001/XMLSchema#string